Please assess the completion status of the following clinical trial:

Trial Title: Chemotherapy and Radiation Therapy in Treating Patients With Stage III or Stage IV Larynx or Oropharynx Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed stage III or IV (T2-T4) squamous cell carcinoma of the larynx or oropharynx~  * No recurrent disease~ * No evidence of distant metastasis~* Resectable disease, defined as follows:~  * High probability of attaining clear surgical margins (for disease of the base of tongue, tonsil, soft palate, or pharyngeal wall)~ * No extension to root of tongue (for disease of the base of tongue)~ * No extension into pterygoid by radiograph (for disease of the tonsil, soft palate, or pharyngeal wall)~ * No primary tumor or nodal metastases fixed to the carotid artery or cervical spine (for disease of the base of tongue, tonsil, soft palate, or pharyngeal wall)~ * No trismus (for disease of the tonsil, soft palate, or pharyngeal wall)~ * No involvement of the trachea greater than 1 cm or any involvement of the esophagus (for disease of the subglottis)~ * For disease of the supraglottis, glottis, or subglottis:~    * No base of the tongue invasion greater than 2 cm~   * No tumor extension through cartilage to involve strap muscles of the neck~   * No tumor fixation to prevertebral fascia~   * No involvement of the carotid artery~   * No fixed nodal disease with involvement of the deep neck~   * Extension into pyriform sinus or lateral pharyngeal wall allowed if no extension into posterior pharynx~* Measurable disease~  * - Lesions accurately measured in at least one dimension as \> 20 mm (2.0 cm) with conventional techniques or as \> 10 mm (1.0 cm) with spiral CT scan~ * Cytologic or histologic evidence of neoplasm is needed for measurable disease restricted to a solitary lesion~* No other concurrent head and neck neoplasms~PATIENT CHARACTERISTICS:~Age~* 18 and over~Performance status~* ECOG 0-2~Life expectancy~* Not specified~Hematopoietic~* Absolute neutrophil count at least 1,500/mm\^3~* Platelet count at least 100,000/mm\^3~Hepatic~* Not specified~Renal~* Creatinine less than 3.0 mg/dL~* Calcium normal~Cardiovascular~* No significant cardiac disease~* No uncontrolled hypertension~* No unstable angina~* No congestive heart failure~* No myocardial infarction within the past year~* No serious cardiac arrhythmias requiring medication~Other~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception during and for at least 3 months after study completion~* No significant detectable infection~* No history of allergy to drugs containing Cremophor EL~* No history of allergy to mammalian cell-derived products (epoetin alfa) or human albumin~* No other malignancy within the past 3 years except basal or squamous cell skin cancer or carcinoma in situ of the cervix~PRIOR CONCURRENT THERAPY:~Biologic therapy~* Not specified~Chemotherapy~* No prior chemotherapy~* No concurrent amifostine~Endocrine therapy~* Not specified~Radiotherapy~* No prior radiotherapy above the clavicles~Surgery~* No prior surgery to the primary tumor except biopsy or debulking~Other~* No concurrent experimental mucosal protectants

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).